3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
5
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
7
Lymphoma, Non-Hodgkin
4
Leukemia
4
Lymphoma, Follicular
3
Lymphoma
3
Leukemia, B-Cell
3
Waldenstrom Macroglobulinemia
2
Neoplasms
2
Lymphoma, Mantle-Cell
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Hematologic Neoplasms
1
Burkitt Lymphoma
1
Interventions
Gemcitabine
34
pembrolizumab
26
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
ofatumumab
×
Clear all
NCT01077518
2020-03-27
A+B
Novartis
Phase 3
Terminated
346 enrolled
41 charts
NCT00748189
2019-06-25
COMPLEMENT 1
Novartis
Phase 3
Terminated
447 enrolled
32 charts